Bioceros appoints Mark Treherne as chairman of the Supervisory Board
Bioceros B.V. announced the appointment of Dr J. Mark Treherne to join and chair its Supervisory Board.
Mark Treherne (1961), PhD, obtained his PhD in receptor neuropharmacology from Cambridge University (UK) with funding from Merck, before holding a faculty position at the Biozentrum in Basel (Switzerland). Mark now has over 20 years experience in the discovery of novel therapeutic treatments and was formerly at Pfizer in the UK, where he was responsible for research into neurodegenerative diseases. On leaving Pfizer in 1997, Mark set up Cambridge Drug Discovery as Chief Executive, which was sold to BioFocus (now a part of Galapagos (Belgium)). Mark is also Chairman of NeuroDiscovery Ltd (Australia) and Cyclofluidic Limited (UK) and a director of Senexis Limited (UK), Population Genetics Technologies Limited (UK) and Domain Therapeutics S.A. (France).
Other news from the department people
